Dupilumab De-escalation in Pediatric Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE4

Conditions

Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Johns Hopkins Univerisity, Baltimore, Maryland, United States
Contact: Study coordinator (Zeena Mestari, BA) · Zmestar1@jh.edu · 848-702-4101

Study leads

Joy Wan, MD MSCE
Principal Investigator
Johns Hopkins University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Atopic Dermatitis · Sleep Disturbance

Abroad (travel likely)RecruitingPHASE4

Chicago, United States

Ethnic Differences in Mechanisms of Action of Dupilumab

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE4

Ann Arbor, United States

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Bryant, United States

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

St. Petersburg, United States